Newmark Group Inc. has successfully arranged the sale of the Burlington BioCenter, a premier life science facility located in Burlington, Massachusetts. The transaction was led by Newmark Co-Head of U.S. Capital Markets Robert Griffin, alongside other key executives. The buyer, an owner-user, has chosen to remain unnamed. The Burlington BioCenter, completed in 2019 with interior laboratory buildouts finished in 2022, features state-of-the-art laboratory infrastructure and premium finishes. Situated at 4 Burlington Woods Drive, the property offers excellent accessibility and is part of a thriving suburban life science cluster. Comprising 109,085 square feet across four stories, it stands out in the Burlington submarket for its turnkey laboratory infrastructure and immediate occupancy potential.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.